Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 85, Issue 3, Pages 241-246Publisher
WILEY
DOI: 10.1038/clpt.2008.277
Keywords
-
Categories
Ask authors/readers for more resources
Measuring the benefits and risks of medicines is the underlying theme whenever the development, review, and regulation of new medicines are discussed. Workshop participants were asked to take the first steps toward defining a framework for benefit-risk (BR) assessment. The framework identifies the essential elements that both regulators and companies should consider throughout the development, review, and postmarketing experience of new medicines in order to apply a consistent approach toward the assessment of BR balance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available